Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2023 Apr 13

PMID 37052811

Authors

Prateek Pophali

Sudhamsh Reddy Desai

Aditi Shastri

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To discuss novel targeted therapies under investigation for treatment of myelodysplastic neoplasms (MDS).

Recent Findings: Over the last few years, results of phase 3 trials assessing novel therapies for high-risk MDS have been largely disappointing. Pevonedistat (NEDD-8 inhibitor) and APR-246 (TP53 reactivator) both did not meet trial endpoints. However, early phase trials of BCL-2, TIM3, and CD47 inhibitors have shown exciting data and are currently under phase 3 investigation. Moreover, combination of hypomethylating agents (HMA) with novel therapies targeting the mutational (IDH, FLT3, spliceosome complex) or immune (PD-1/PDL-1, TIM-3, IRAK-4) pathways are being investigated in early phase clinical trials and have shown adequate safety and promising efficacy. Myelodysplastic neoplasms (MDS) are a group of hematopoietic neoplasms defined by cytopenias and morphological dysplasia. They are characterized by clonal proliferation of aberrant hematopoietic stem cells caused by recurrent genetic abnormalities. This leads to ineffective erythropoiesis, peripheral blood cytopenias, abnormal cell maturation, and a high risk of transformation into acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation is the only curative therapy; however, it is not a suitable option for majority patients due to their age, comorbidities, and the high rate of treatment-related complications. HMAs remain the only FDA-approved treatment option for high-risk MDS. Due to intolerance, primary, and secondary resistance to HMA, there is a large unmet need to develop new safe and effective therapies for patients with MDS. In this review, we focus on the current management strategies and novel therapies in development for treatment of high-risk MDS.

References

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Cazzola M . Myelodysplastic Syndromes. N Engl J Med. 2020; 383(14):1358-1374. DOI: 10.1056/NEJMra1904794. View

Chakraborty S, Shapiro L, de Oliveira S, Rivera-Pena B, Verma A, Shastri A . Therapeutic targeting of the inflammasome in myeloid malignancies. Blood Cancer J. 2021; 11(9):152. PMC: 8440507. DOI: 10.1038/s41408-021-00547-8. View

Flores-Figueroa E, Gutierrez-Espindola G, Montesinos J, Arana-Trejo R, Mayani H . In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res. 2002; 26(7):677-86. DOI: 10.1016/s0145-2126(01)00193-x. View

Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L . IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015; 125(20):3144-52. PMC: 4432009. DOI: 10.1182/blood-2015-01-621631. View

Neukirchen J, Schoonen W, Strupp C, Gattermann N, Aul C, Haas R . Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res. 2011; 35(12):1591-6. DOI: 10.1016/j.leukres.2011.06.001. View

Cogle C, Craig B, Rollison D, List A . Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011; 117(26):7121-5. PMC: 3143554. DOI: 10.1182/blood-2011-02-337964. View

de Swart L, Smith A, Johnston T, Haase D, Droste J, Fenaux P . Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015; 170(3):372-83. DOI: 10.1111/bjh.13450. View

Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lubbert M, Martino S . Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res. 2013; 38(1):57-64. DOI: 10.1016/j.leukres.2013.10.013. View

10.

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

11.

Pfeilstocker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sole F . Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016; 128(7):902-10. PMC: 5161006. DOI: 10.1182/blood-2016-02-700054. View

12.

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M . A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011; 118(14):3765-76. DOI: 10.1182/blood-2011-01-330126. View

13.

Fenaux P, Platzbecker U, Mufti G, Garcia-Manero G, Buckstein R, Santini V . Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020; 382(2):140-151. DOI: 10.1056/NEJMoa1908892. View

14.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

15.

Kantarjian H, Issa J, Rosenfeld C, Bennett J, Albitar M, DiPersio J . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106(8):1794-803. DOI: 10.1002/cncr.21792. View

16.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

17.

Stomper J, Rotondo J, Greve G, Lubbert M . Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021; 35(7):1873-1889. PMC: 8257497. DOI: 10.1038/s41375-021-01218-0. View

18.

Silverman L, Demakos E, Peterson B, Kornblith A, Holland J, Odchimar-Reissig R . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429-40. DOI: 10.1200/JCO.2002.04.117. View

19.

Prebet T, Gore S, Esterni B, Gardin C, Itzykson R, Thepot S . Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011; 29(24):3322-7. PMC: 4859209. DOI: 10.1200/JCO.2011.35.8135. View

20.

Zeidan A, Salimi T, Epstein R . Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?. Future Oncol. 2021; 17(36):5163-5175. DOI: 10.2217/fon-2021-0936. View